Last reviewed · How we verify
IVACFLU
At a glance
| Generic name | IVACFLU |
|---|---|
| Also known as | whole virion monovalent A/H1N1 influenza vaccine |
| Sponsor | PATH |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam (PHASE3)
- Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3 (PHASE2, PHASE3)
- A Safety and Immunogenicity Study of IVACFLU-A/H5N1 (PHASE2, PHASE3)
- Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1 (PHASE1)
- Safety Trial of Monovalent Whole Virus Influenza (H1N1) Vaccine (PHASE1)
- Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IVACFLU CI brief — competitive landscape report
- IVACFLU updates RSS · CI watch RSS
- PATH portfolio CI